Why carry out this study?

In the SUSTAIN phase 3 clinical trial programme, once-weekly (OW) semaglutide demonstrated superior, clinically relevant glycaemic and body weight reductions versus a wide range of comparators in people with type 2 diabetes (T2D).

Real-world evidence on the use of OW semaglutide in routine clinical practice is needed to augment these clinical trial findings.

The SURE programme, which was conducted across 10 countries, investigated the use of OW semaglutide in patients with T2D in real-world clinical practice.

Here, we report the results of SURE UK, a prospective, multicentre, single-arm, open-label, observational study.

What was learned from the study?

In real-world clinical practice, patients receiving OW semaglutide experienced statistically significant and clinically relevant glycaemic and body weight reductions; no new safety concerns were observed.